Table 5 The multivariate analysis for the PFS.

From: The efficacy and safety of thymosin alpha-1 combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma: a retrospective study

 

PFS

HR

95% CI

P value

PT, second (≤ 16 vs. > 16)

0.496

0.303–0.812

0.005

Therapeutic regimen (control vs. experimental)

0.467

0.340–0.945

0.029

AFP, ng/ml (≤ 200 vs. > 200)

0.685

0.408–1.149

0.152

  1. PFS: Progression free survival. Significant values are in bold.
Back to article page